1、,头颈部肿瘤,头颈部肿瘤概述口腔肿瘤新辅助化疗2015 ASCO,流行病学,占全身恶性肿瘤的5第6大常见的恶性肿瘤肿瘤相关死亡原因的第8位头颈部肿瘤的患者有可能罹患第2个原发性的头颈部、肺部或食管的肿瘤,病因,吸烟和嗜酒口咽癌：人乳头瘤病毒(HPV) 60-70%鼻咽癌：EBV,HPV+口咽部肿瘤的疗效和生存情况均比HPV- 的肿瘤要好,治疗前血浆EBV-DNA水平越高，则治疗后出现远处转移的概率越高；监测随访,Humanpapillomavirusandsurvivalofpatientswithoropharyngeal cancer. N Engl J Med.2010 Jul 1;36
2、3(1):24-35.,头颈部肿瘤特点,90%以上EGFR过表达以鳞癌为主视、听、嗅觉、呼吸、发声、进食、容貌局部结构复杂、险隘，安全边缘有限“不可切除的病变” 没有定义,不同部位特点不同,喉癌：声门上区肿瘤在确诊时通常已经为局部晚期；但是声门区肿瘤发现时多为早期，治愈率非常高：约80%90%咽癌：大约60%的下咽部肿瘤患者已属局部晚期伴区域淋巴结转移，预后通常都很差,分期,唇部、口腔及口咽部肿瘤根据瘤体大小界定T分期声门区、声门上区、喉咽及鼻咽部肿瘤根据各自亚区侵犯情况界定T分期除了鼻咽癌的区域淋巴结（N）分期之外，对于不同部位肿瘤的N及远处转移（M）的界定标准是一致的喉、口咽、下咽：VII
3、区（上纵膈）转移也被认为是区域淋巴结转移,治疗特点,T1-2N0M0期: 单纯手术或单纯放疗局部晚期: 手术+放疗+化疗复发和转移，姑息性化疗放疗+化疗+手术鼻咽癌主要以放化疗为主,新辅助治疗,例如：对可手术切除的局部晚期喉癌、咽癌，术前诱导化疗/同步放化疗不仅可以提高保喉率，而且可提高患者生存率,放疗,原发病灶和受侵淋巴结需要每天2.0 Gy，总量为70 Gy或以上的剂量对于颈部风险较低的淋巴结群的放疗剂量为每天2.0 Gy，总量50 Gy或以上,化疗,新辅助化疗同步放化疗（根治性、辅助性）辅助化疗姑息化疗,靶向治疗,西妥昔单抗 早中期：同步放疗 晚 期：单药或联合化疗尼妥珠单抗（nimot
4、uzumab）吉非替尼、厄洛替尼：未观察到临床受益,不良预后因素,淋巴结包膜外受侵和/或手术切缘阳性：术后进行辅助性化放疗其他不良预后因素：多个阳性淋巴结（无包膜外受侵）、血管/淋巴管/神经周围侵犯、原发肿瘤T4a及具有IV区淋巴结阳性术后放疗，但是否进行放化疗可根据临床判断,复发和(或)转移,复发病变可治愈：应积极寻求根治性手术 或同步放化 （靶）疗无局部治愈可能：姑息性化疗和(或)靶向治疗 支持治疗,姑息化疗的中位生存时间大约为6个月，1年生存率大约为20%,Induction Chemotherapy,Induction chemotherapy plus radiation compa
5、red with surgery plus radiation in patients with advanced laryngeal cancer. The Department of Veterans Affairs Laryngeal Cancer Study GroupN Engl J Med.1991;324(24):1685,332 ptsmedian follow-up of 33 monthssurgery +radiotherapyinduction chemotherapy+ radiotherapySalvage surgerycisplatin +fluorouraci
6、（PF）,Focus on larynx preservation,2-year survival: 68% : 68%,P=0.1195,Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial.EORTCHead and Neck Cancer Cooperative Group J Natl Cancer Inst.1996,202 ptssurgery +
7、radiotherapyinduction chemotherapy+ radiotherapySalvage surgerycisplatin +fluorouraci（PF）,Focus on larynx preservation,Induction-chemotherapy arm vs. Surgery arm,OS: 44 : 25 months3-year survival: 57% : 43%PFS: 25 : 20 months,TPF vs. PF,Induction chemotherapy with cisplatin and fluorouracil alone or
8、 in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial. Lancet Oncol.2011;12(2):153-9,Median follow-up of 6.0 years (72.2 months)55 centers 501 patients,http:/www.ncbi.nlm.nih.gov/pmc/articles/PMC4356902
9、/pdf/nihms667891.pdf,OS: 70.6 vs. 34.8 mo,PFS: 38.1 vs. 13.2 mo,hypopharyngeal and laryngeal,PFS: 20.9 vs. 10.1 mo,OS: 51.9 vs. 23.5 mo,Long-term results of GORTEC 2000-01: A multicentric randomized phase III trial of induction chemotherapy with cisplatin plus 5-fluorouracil, with or without docetax
10、el, for larynx preservation. France213 ptsMedian follow-up 105 months TPF vs. PFThe 5- and 10-year larynx preservation rates 74.0% vs. 58.1% 70.3% vs. 46.5%The 5- and 10-year LDFFS rates 67.2% vs. 46.5% 63.7% vs. 37.2% OS, PFS no difference (LDFFS :larynx dysfunction-free survival),ASCO2015,Taxane-c
11、isplatin-fluorouracil as induction chemotherapy for advanced head and neck cancer: a meta-analysis of the 5-year efficacy and safety. Springerplus.2015;4:208.7 randomized clinical (mata analysis) TPF vs. PF 3-year OS rate (HR: 1.14; 95% CI: 1.03 to 1.25; P=0.008) 3-year PFS rate (HR: 1.24; 95% CI: 1
12、.08 to 1.43; P=0.002) 5-year OS rate (HR: 1.30; 95% CI, 1.09 to 1.55;P=0.003) 5-year PFS rate (HR: 1.39; 95% CI, 1.14 to 1.70; P=0.001)The TPF induction chemotherapy improved PFS and OS compared with PF,Induction Chemotherapy vs. Concurrent ChemoRT,Long-Term Results of RTOG 91-11: A Comparison of Th
13、reeNonsurgical Treatment Strategies to Preserve the Larynx inPatients With Locally Advanced Larynx Cancer J Clin Oncol 2013;31:845-852,Patients with stage III or IV glottic or supraglottic squamous cell cancerlaryngectomy-free survival (LFS),(PF),For selected patients with hypopharyngeal and larynge
14、al cancers less than T4a in extent, inductionchemotherapyused as part of a larynx preservation strategyis category 2A,Thus, induction chemotherapy has a category 3recommendation for the management of both locally and regionally advanced oropharyngeal cancer,Induction Chemotherapy in Oral Squamous Ce
15、ll Carcinoma,Randomized Phase III Trial of Induction Chemotherapy With Docetaxel, Cisplatin, and Fluorouracil Followed by Surgery Versus Up-Front Surgery in Locally Advanced Resectable Oral Squamous Cell Carcinoma J Clin Oncol.2013 ;31(6):744-51,256 patientsLocallyadvancedResectable Oral Squamous Ce
16、ll Carcinoma, TPFMedian follow-up of 30 months,cN2,Induction chemotherapy + Concurrent chemoradiotherapy,Induction chemotherapy followed by concurrentchemoradiotherapy (sequential chemoradiotherapy) versusconcurrent chemoradiotherapy alone in locally advanced headand neck cancer (PARADIGM): a random
17、ised phase 3 trialLancet Oncol 2013; 14: 25764,145 patients across 16 sitesMedian follow-up of 49 months Induction chemotherapy + Concurrent chemoradiotherapy Concurrent chemoradiotherapy,3-year overall survival was 73% vs. 78%,OS,PFS,Phase III randomized trial ofinduction chemotherapyin patients wi
18、th N2 or N3 locally advancedhead and neck cancer. J Clin Oncol.2014; 32(25):2735285 patients , with N2 or N3 diseaseFollow-up of 30 monthsInduction chemotherapy + Concurrent chemoradiotherapy Concurrent chemoradiotherapyNO difference: OS, Relapse-FreeSurvival , Distant Failure-Free Survival,Is there
19、 a role for induction chemotherapy in the setting of concomitant chemoradiation in locally advanced head and neck cancer: A systematic review and meta-analysis of randomized controlled trials,Meta-analysis, 5 RCTs ( 4 TPF, 1 PF )1229 patientsIndu-chemotherapy + concomitant chemoradiation concomitant
20、 chemoradiationOS, PFS no difference have a trendDisease control , CR Imply that selected patients may benefit from the addition of induction chemotherapy,ASCO2015,New aspects regarding the induction chemotherapy with TPF and radio chemotherapy in head and neck cancer GermanyMeta-analysis, 5 RCTs (T
21、PF)1060 patients, locally advanced53.4% oropharyngeal, 17.3% hyopharyngeal, 6.4% laryngeal, 18.5% oral cavity , 4.4% other SCCHNTPF + concomitant chemoradiation concomitant chemoradiationNot result in a significant improvement of OS (Hazard Ratio: 0.950, 0.791-1.140, p = 0.579),ASCO2015,Radiotherapy
22、 plus cetuximab,Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival Lancet Oncol.2010 ;11(1):21-8,424 pts: locoregionally advanced squamous-cell carcinoma (orophar
23、ynx, hypopharynx, or larynx)73 centresmedian follow-up 60 monthsradiotherapy aloneradiotherapy plus cetuximabOS: 49.0 months versus 29.3 months5-year overall survival was 45.6% versus 36.4%,Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for st
24、age III to IV head and neck carcinoma: RTOG 0522. J Clin Oncol.2014 Sep 20;32(27):2940-50.,891 analyzed patientsMedian follow-up 3.8 yearsCetuximab plus cisplatin-radiationcisplatin-radiation alone,3-year PFS (61.2% v. 58.9%, P = .76), 3-year OS (72.9% v. 75.8, P = .32)p16-positive compared with p16
25、-negative PFS (72.8% v. 49.2%, P .001) OS (85.6% v. 60.1%, P .001),EGFR expression did not distinguish outcomeShould not be prescribed routinely,Oral Cavity,Very advanced,2015 ASCOHead and Neck Cancer,Phase III randomized trial of standard fractionation radiotherapy with concurrent cisplatin versus
26、accelerated fractionation radiotherapy with panitumumab in patients with locoregionally advanced squamous cell carcinoma of the head and neck: NCIC Clinical Trials Group HN.6 trialCanada320 pts With a median follow-up of 46.4 monthsPFS of PMab +AFX was not superior to CIS +SFX,Weekly paclitaxel, car
27、boplatin, cetuximab (PCC), and cetuximab, docetaxel, cisplatin, and fluorouracil (C-TPF), followed by risk-based local therapy in previously untreated, locally advanced head and neck squamous cell carcinoma (LAHNSCC) MD Anderson Cancer Centerphase IIMedian follow-up of 18.4 months 136 patients,Mutat
28、ional patterns of HPV + and HPV- squamous cell carcinomas of the head and neck (SCCHN) and their interference with outcome after adjuvant chemoradiation: A multicenter biomarker study of the German Cancer Consortium Radiation Oncology Group Germany208 patients211 exons from 45 genes HPV +： enriched
29、for activating mutations in driver genes (PIK3CA 27% , KRAS 8%, NRAS 4%, HRAS 2%) HPV- ：loss-of-function alterations in tumor suppressor genes (TP5367%, CDKN2A 30%, PTEN 4%, SMAD4 3%) median follow-up of 55 months, loss-of-function tumor suppressor gene mutations negatively interfere with efficacy o
30、f adjuvant cisplatin-based chemoradiation, whereas activating driver gene mutations define poor risk specifically in HPV-driven SCCHN,Antitumor activity and safety of pembrolizumab (MK-3475) in patients with advanced squamous cell carcinoma of the head and neck: Preliminary results from KEYNOTE-012
31、expansion cohort ChicagoORR(Objective Response Rate) was 18.2%31.3% with stable diseaseBiomarker analysis is ongoing,Final overall survival analysis of EXAM, an international, double-blind, randomized, placebo-controlled phase III trial of cabozantinib (Cabo) in medullary thyroid carcinoma (MTC) pat
32、ients with documented RECIST progression at baseline. France是RET，VEGFR2和MET酪氨酸激酶的强效抑制剂，于2012年11月被美国FDA批准用于MTC的治疗median follow up time 52.4 moN= 330median OS 26.6 mo vs 21.1 mo ( p = 0.241). median OS 44.3 mo vs 18.9 mo (p = 0.026) , For 126 pts with RET M918T mutations,Efficacy and safety of lenvati
33、nib for the treatment of patients with 131I-refractory differentiated thyroid cancer with and without prior VEGFtargeted therapy. London PFS 18.3 vs. 3.6 mo2015.4 FDA,Utilization and outcomes of low dose versus high dose cisplatin in head and neck cancer patients receiving concurrent radiation. Milw
34、aukee1,091 ptsLD ( 40 mg/m2) ， HD ( 75 mg/m2) The total cumulative dose 322.5 mg vs. 475.8 mgOS favoring the HD group(log rank test, p 0.001) 75% censored in both cohorts,Differential impact of cisplatin dose intensity on human papillomavirus (HPV)-related ( + ) and HPV-unrelated ( - ) locoregionall
35、y advanced head and neck squamous cell carcinoma (LAHNSCC). Canada （retrospective）Median follow-up was 4.3 yrs5 year OS was inferior for HPV（ - ）CDDP 200 vs. 200 mg/m2 (44 % vs 62%, p 0.01)But not to HPV（ +）,A meta-analysis of weekly cisplatin versus three weekly cisplatin chemotherapy plus current
36、radiotherapy for advanced head and neck cancer. Yue Zhang Southern Medical University, Guangzhou, China779 patients of 10 studies Three weekly cisplatin CRT didnt differ with weekly in OS and LRFS(locoregional recurrence-free survival),A meta-analysis comparing cisplatin-based to carboplatin-based c
37、hemotherapy in moderate to advanced squamous cell carcinoma of head andneck (SCCHN). Qinyang Li, Nanfang Hospital, Southern Medical University, Guangzhou, ChinaPatients with CDDP-based CT can achieve a higher OS, but there is no significant difference in LRC,Bioradiotherapy for head and neck cutaneo
38、us squamous cell carcinoma , Philadelphia68 patients Median follow-up 30 months,Phase II study with conventional radiotherapy + cetuximab in patients with advanced larynx cancer who responded to induction chemotherapy : An organ preservation TTCC study. Spain93 patients , one armMedian follow-up: 48
39、 monthsLEDFS(the laryngo-esophageal dysfunctionfree survival ) rate was clearly higher than the critical value and with an acceptable toxicity with this protocol, so it is warranted to move to a phase III trial,The role of cetuximab in induction chemotherapy: Comparison of APF-C( nab-paclitaxel, cis
40、platin, 5-FU+ cetuximab) with APF, both followed by chemoradiation therapy (CRT), in patients with locally advanced head andneck squamous cell carcinoma (HNSCC). St. LouisBackground: Cetuximab improved OS in patients with HNSCC when added to definitive RT or to palliative chemotherapy60 pts Two year
41、 OS and DSS(disease-specific survival) were similar between APF+C and APF, even when stratified for p16 status.,Concurrent chemoradiation using weekly versus tri-weekly cisplatin in locally advanced squamous cell carcinoma of the head and neck (SCCHN): A comparative analysis. AtlantaOut of 120 studi
42、es, 23 with a total of 2,303 patients Weekly cisplatin combined with radiation in locally advanced SCCHN is comparable in efficacy and safety to tri-weekly based regimens.,总结,个体化治疗，综合和治疗对部分选择的患者，诱导化疗是可行的，在局部疾病控制、器官保留方面可以带来益处，能降低远处转移发生率，并有可能转化为生存获益诱导化疗仍缺乏有效的筛选标记靶向治疗，特别是免疫治疗未来会带来突破,THANKS,同步放化疗随机临床试验支
43、持几种顺铂的使用方案（例如每周，每天，但大多数医疗中心采用高剂量顺铂治疗（每3周100 mg/m2）,口腔癌,口腔癌,口腔癌,鼻咽癌,在头颈部肿瘤中，它具有最高的远处转移倾向。局部晚期鼻咽癌在根治性放疗（未行化疗）后很容易出现孤性局部复发。区域复发不常见，仅占患者的10%19%治疗前血清/血浆中EBV-DNA水平与早期鼻咽癌(I期和II期)的预后有关，治疗前血浆EBV-DNA水平越高，则治疗后出现远地转移的概率越高联合使用放疗和铂类药物化疗已被证实肿瘤的局部控制率可以从54%增加到78%,鼻咽部肿瘤患者治疗后，推荐的随访内容包括定期体检和甲状腺功能的评估（每612个月检测TSH水平）在20%2
44、5%的接受颈部放疗的患者当中可检测出TSH水平增高,鼻咽癌,初始治疗决策,手术放疗同步放化疗新辅助化疗,唇、口腔、咽、喉、鼻窦、涎腺等,pembrolizumab是西妥昔单抗疗效(1013%)的约两倍EGFR-抑制剂在HPV-阳性肿瘤中疗效不佳pembrolizumab在HPV-阳性和HPV-阴性肿瘤中均有相似活性水平缓解率可能低估患者的获益比例病情稳定或即使最初经历疾病进展的患者一旦接受免疫治疗最终可能变为长期生存期的获益,Nonetheless, interest in the role of induction chemotherapy was renewed several years
45、 ago for a few reasonsAdvances in surgery, RT, and concurrent systemic therapy/RT have yielded improvements in local/regional control thus, the role of distant metastases as a source of treatment failure has increased and induction chemotherapy allows greater drug delivery for this purpose,Most rand
46、omized trials of inductionchemotherapy followed by RT and/or surgery compared to locoregional treatment alone, which were published in the 1980s and 1990s, did not show an improvement in overall survival with the incorporationof chemotherapy.273in selected patients, induction chemotherapy couldfacilitate organ preservation, avoid morbid surgery, and improve overall quality of life of the patient even though overall survival was not improved. Because total laryngectomy is among the procedures mostfeared by patients,281 larynx preservation was the focus of initial studies,
